DelveInsight’s, “Acne Vulgaris Pipeline Insight 2023” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the Acne Vulgaris pipeline landscape. It covers the Acne Vulgaris pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Acne Vulgaris Pipeline Report

• DelveInsight’s Acne Vulgaris pipeline report depicts a robust space with 22+ active players working to develop 22+ pipeline therapies for Acne Vulgaris treatment.
• The leading companies working in the Acne Vulgaris Market include Novan, Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio, Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea, Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.
• Promising Acne Vulgaris Pipeline Therapies in the various stages of development include Tazarotene, Trifarotene 0.005 % Topical Cream, AKLIEF®, Sarecycline, Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), and others.
• October 2023: Taro Pharmaceuticals USA announced a study of phase 1 clinical trials for Trifarotene Cream 0.005%. To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris.
• September 2023: Cutia Therapeutics (Shanghai) Co. Ltd announced a study of Phase 3 clinical trials for FMX101. This is a randomized, multicenter, double-blind, vehicle-controlled, 2-arm study to evaluate the safety and efficacy in 12 weeks of FMX101 minocycline foam, 4%, compared to vehicle, in the treatment of subjects with moderate to severe facial acne vulgaris.

 

Request a sample and discover the recent advances in Acne Vulgaris Treatment Drugs @ Acne Vulgaris Pipeline Report

 

In the Acne Vulgaris pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA).

 

Find out more about Acne Vulgaris Therapeutics Assessment @ Acne Vulgaris Preclinical and Discovery Stage Products

 

Acne Vulgaris Emerging Drugs Profile

• IDP126: Bausch Health Americas, Inc.
• DMT310: Dermata Therapeutics

 

Acne Vulgaris Pipeline Therapeutics Assessment

There are approx. 22+ key companies which are developing the Acne Vulgaris therapies. The Acne Vulgaris companies which have their Acne vulgaris drug candidates in the most advanced stage, i.e. Phase III include, Bausch Health Americas, Inc.

 

Learn more about the emerging Acne Vulgaris Pipeline Therapies @ Acne Vulgaris Clinical Trials Assessment

 

Scope of the Acne Vulgaris Pipeline Report

• Coverage- Global
• Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Acne Vulgaris Companies- Novan, Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio, Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea, Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.
• Acne Vulgaris Pipeline Therapies- Tazarotene, Trifarotene 0.005 % Topical Cream, AKLIEF®, Sarecycline, Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), and others.

 

Dive deep into rich insights for new drugs for Acne Vulgaris Treatment, Visit @ Acne Vulgaris Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Acne vulgaris: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. IDP126: Bausch Health Americas, Inc.
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. DMT310: Dermata Therapeutics
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. ORG101: Origimm Biotechnology
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Acne vulgaris Key Companies
17. Acne vulgaris Key Products
18. Acne vulgaris- Unmet Needs
19. Acne vulgaris- Market Drivers and Barriers
20. Acne vulgaris- Future Perspectives and Conclusion
21. Acne vulgaris Analyst Views
22. Acne vulgaris Key Companies
23. Appendix

 

For further information on the Acne Vulgaris Pipeline therapeutics, reach out to Acne Vulgaris Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking